Five9 Inc vs Smith & Nephew plc — how do they compare? Five9 Inc trades at $36.04 (market cap $2.63B), while Smith & Nephew plc trades at $27.23 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 4.2× Five9 Inc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Five9 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and Smith & Nephew plc for 121 Days on average.
| FIVN | SNN | |
|---|---|---|
Market Cap | $2.63B | $11.10B |
Volume | 1,864,393 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $38.65 | $37.17 |
52-Week Low | $13.61 | $26.42 |
Typical Hold Time | 72 Days | 121 Days |
Enterprise Value | $2.78B | $14.13B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $35.10, up 3.91% with strong technical momentum near recent highs. The company shows accelerating revenue growth, reaching $1.15B in 2025 with improving profitability (net margin 4.94%). Recent quarters have consistently beaten EPS estimates, while AI revenue surged 78% YoY to $39M in Q2 2026. Analyst sentiment remains bullish with 61% buy ratings and a $34 consensus target.
Outlook remains positive driven by AI contact center adoption and subscription growth, though high valuation multiples (P/E 51.7) and insider selling present near-term risks. The stock's technical setup suggests continued upside if it maintains above $34 support, but investors should monitor debt levels and competitive pressures in the CCaaS space.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →